top of page

GenoBrain DNA Test for Brain Health, Mental Wellness & Medication Response

GenoBrain is a personalized DNA test that provides insights into genetic factors associated with brain health, neurological conditions, mental wellness, behavioural traits and medication response. Using a simple cheek-swab sample, the test evaluates selected genetic markers related to conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, ALS, migraine, ADHD, depression, bipolar disorder and schizophrenia. It may also provide information about stress response, anxiety control, emotional resilience, learning ability, social skills and emotional awareness.

​

Your personalized GenoBrain report includes a clear summary of your genetic findings, estimated risk levels for selected conditions, explanations of relevant genes and general wellness recommendations. It also includes pharmacogenomic insights that may indicate how your body could metabolize or respond to certain antidepressants, neurological medications, mood stabilizers and other mental-health medications. GenoBrain does not diagnose a medical condition or determine which medication you should take. Results should be reviewed alongside your symptoms, medical history and family history with a qualified healthcare professional.l.

Hand Holding Brain

GenoBrain

Your brain health, emotional well-being, cognitive traits, and response to certain medications can be influenced by genetics. GenoBrain analyzes selected genes associated with neurological conditions, mental health, stress response, learning ability, emotional resilience, and pharmacogenomic response to provide personalized insights into your brain health.

Key Genes Analyzed:
  • SLC6A2: Associated with attention regulation and genetic susceptibility to ADHD.

  • COMT: Influences dopamine activity, stress resilience, pain threshold, and emotional response.

  • DRD2: Associated with dopamine signalling and feedback-based learning.

  • FKBP5, OPRM1, and GABRA6: Linked to stress response, emotional regulation, and anxiety-related traits.

  • CACNA1C and MET: Associated with emotional processing, facial emotion recognition, and selected neuropsychiatric traits.

  • SNCA, MAPT, LRRK2, and NUCKS1: Evaluated in relation to genetic susceptibility to Parkinson’s disease.

Unique Features:
  • Assessment of genetic susceptibility to conditions such as Alzheimer’s disease, Parkinson’s disease, migraine, multiple sclerosis, ALS, ADHD, depression, bipolar disorder, and schizophrenia.

  • Personalized insights into stress control, anxiety response, emotional resilience, learning ability, personality, and emotional awareness.

  • Pharmacogenomic information related to selected antidepressants, mood stabilizers, antipsychotics, neurological medications, and cognitive-support medications.

  • Personalized lifestyle and wellness recommendations to support long-term brain health.

  • Professional review of results in the context of medical history, symptoms, family history, and current medications.

bottom of page